CN117015375A - 用于治疗由冠状病毒引起的急性呼吸窘迫综合征(ards)和炎性病症的组合物和方法 - Google Patents

用于治疗由冠状病毒引起的急性呼吸窘迫综合征(ards)和炎性病症的组合物和方法 Download PDF

Info

Publication number
CN117015375A
CN117015375A CN202180059368.3A CN202180059368A CN117015375A CN 117015375 A CN117015375 A CN 117015375A CN 202180059368 A CN202180059368 A CN 202180059368A CN 117015375 A CN117015375 A CN 117015375A
Authority
CN
China
Prior art keywords
drug
sars
inflammatory
agent
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059368.3A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·L·张
本·Y·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foer Medical Co
Original Assignee
Foer Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foer Medical Co filed Critical Foer Medical Co
Publication of CN117015375A publication Critical patent/CN117015375A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180059368.3A 2020-05-28 2021-05-27 用于治疗由冠状病毒引起的急性呼吸窘迫综合征(ards)和炎性病症的组合物和方法 Pending CN117015375A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031551P 2020-05-28 2020-05-28
US63/031551 2020-05-28
PCT/US2021/034494 WO2021243007A2 (en) 2020-05-28 2021-05-27 Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms

Publications (1)

Publication Number Publication Date
CN117015375A true CN117015375A (zh) 2023-11-07

Family

ID=78722786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059368.3A Pending CN117015375A (zh) 2020-05-28 2021-05-27 用于治疗由冠状病毒引起的急性呼吸窘迫综合征(ards)和炎性病症的组合物和方法

Country Status (12)

Country Link
US (3) US20230248684A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304570A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023528804A (cg-RX-API-DMAC7.html)
KR (1) KR20230058014A (cg-RX-API-DMAC7.html)
CN (1) CN117015375A (cg-RX-API-DMAC7.html)
AU (1) AU2021281257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024226A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003348A1 (cg-RX-API-DMAC7.html)
IL (1) IL298593B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014958A (cg-RX-API-DMAC7.html)
WO (1) WO2021243007A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515607A (zh) * 2020-04-16 2022-12-23 联邦高等教育系统匹兹堡大学 用于治疗急性呼吸窘迫综合征的基质结合囊泡(mbv)
CN117919385A (zh) * 2024-02-05 2024-04-26 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2021207497A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 inflammatory cytokine storm treatment
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
CN115252760B (zh) * 2022-03-30 2024-05-31 厦门大学 一种广谱抗冠状病毒的制剂及其制备方法
WO2025029797A1 (en) * 2023-08-01 2025-02-06 Incelldx, Inc. Methods of assigning a covid pathological type and compositions for practicing the same, and methods of treating a subject for chronic covid-19
CN117304031A (zh) * 2023-09-05 2023-12-29 深圳大学 一种铁苋菜二萜类化合物、铁苋菜提取物及其在制备具有抗氧化和/或抗炎作用的产品中的应用
CN117414438B (zh) * 2023-11-01 2025-10-17 大连医科大学附属第一医院 一种靶向m1型巨噬细胞的多肽偶联药物及其应用
CN121490288A (zh) * 2025-11-21 2026-02-10 中山大学附属第三医院 一种用于急性呼吸窘迫综合征的肺部交感神经局部光遗传激活系统及方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908796A (pt) * 1998-03-06 2000-10-31 Fujisawa Pharmaceutical Co Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
US20140364492A1 (en) * 2011-10-26 2014-12-11 Korea Research Institute Of Bioscience And Biotechnology Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464459T3 (es) * 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
US20130203715A1 (en) * 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
JP6977206B2 (ja) * 2016-03-31 2021-12-08 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908796A (pt) * 1998-03-06 2000-10-31 Fujisawa Pharmaceutical Co Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
US20030109486A1 (en) * 2001-10-31 2003-06-12 Eliezer Rapaport Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
US20140364492A1 (en) * 2011-10-26 2014-12-11 Korea Research Institute Of Bioscience And Biotechnology Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRYHUBER, G S ET AL.: "3\'-untranslated region of SP-B mRNA mediates inhibitory effects of TPA and TNF-alpha on SP-B expression", 《THE AMERICAN JOURNAL OF PHYSIOLOGY》, vol. 267, no. 1, 31 July 1994 (1994-07-31), pages 16 - 24 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515607A (zh) * 2020-04-16 2022-12-23 联邦高等教育系统匹兹堡大学 用于治疗急性呼吸窘迫综合征的基质结合囊泡(mbv)
CN117919385A (zh) * 2024-02-05 2024-04-26 中国医学科学院医学实验动物研究所 IL-37在MERS-CoV感染疾病的治疗中的应用

Also Published As

Publication number Publication date
CL2022003348A1 (es) 2023-12-01
JP2023528804A (ja) 2023-07-06
BR112022024226A2 (pt) 2023-01-31
CA3180577A1 (en) 2021-12-02
MX2022014958A (es) 2023-04-13
EP4304570A2 (en) 2024-01-17
AU2021281257A1 (en) 2023-02-02
US20240082202A1 (en) 2024-03-14
WO2021243007A2 (en) 2021-12-02
WO2021243007A3 (en) 2021-12-30
US20260041660A1 (en) 2026-02-12
IL298593A (en) 2023-01-01
EP4304570A4 (en) 2025-01-22
KR20230058014A (ko) 2023-05-02
US20230248684A1 (en) 2023-08-10
IL298593B1 (en) 2026-06-01

Similar Documents

Publication Publication Date Title
US20260041660A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
Clementi et al. Viral respiratory pathogens and lung injury
Perico et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Matsuyama et al. An aberrant STAT pathway is central to COVID-19
Arvin et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2
TW202144383A (zh) 冠狀病毒免疫原性組合物及其等之用途
Ratre et al. Dynamic Propagation and Impact of Pandemic Influenza A (2009 H1N1) in Children: A Detailed Review: YK Ratre et al.
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
AU2021218929A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with IL-22 dimer
KR20240137110A (ko) 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
Patel et al. The immunopathobiology of SARS-CoV-2 infection
WO2022140706A1 (en) Immune-regulatory li-key peptide vaccines for prophylaxis and long-term protection against sars-cov-2 infection and covid-19 disease
US20230295281A1 (en) Natural antibodies in prophylaxis and therapy
Dezfuli et al. Update on immunology of COVID-19 disease and potential strategy for controlling
CN111163792A (zh) 用于治疗病毒感染的肽
JP2023529124A (ja) コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法
Stukova et al. In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract
US20230355725A1 (en) Neil2 protein therapy for treatment of viral infection
Sojati Type III Interferon-Mediated Responses in Upper and Lower Respiratory Tracts During Infection with Human Metapneumovirus Clinical Isolates
Novoa Role of the humoral immune response in the pathophysiology of COVID-19
Yadav et al. Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19
Zhou et al. Unraveling the complexities: A comprehensive review of severe fever with thrombocytopenia syndrome and its associated complications
Wang et al. Roles of Human Respiratory Syncytial Virus Proteins in Immune Responses
WO2022056092A1 (en) Methods of treating viral infection
Clever Improved MVA-based vaccination strategies against COVID-19 in different animal models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231117

Address after: California, USA

Applicant after: Foer Medical Co.

Address before: California, USA

Applicant before: Foer Medical Co.

Applicant before: Richard L. Zhang

Applicant before: Ben. Y. Zhang

TA01 Transfer of patent application right